Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupNeuro-OncologyradiotherapyDiseaseGliomaSubgroupWHO Grade 2WHO grade 2 and 3ICD10C71.-MeSHAstrocytomaGliomaOligodendrogliomaSequenceTMZL75/Radiation, Glioma, C1 (PID1452) -|- C2 (PID1453) -|- C3-13 (PID1454)ChemotherapyChemo-substanceLomustineProcarbazineTemozolomideVincristineChemo-substanceLomustineProcarbazineTemozolomideVincristineChemo-substanceLomustineProcarbazineTemozolomideVincristineChemo-substanceLomustineProcarbazineTemozolomideVincristineNo. Substances13 RadiotherapySupportive therapySupportive substanceAprepitantBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronSupportive substanceAprepitantBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronSupportive substanceAprepitantBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronSupportive substanceAprepitantBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronNo. Substances34Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentioncurativepalliativeRisksAnemia Hb below 8g/dlAstheniaEmetogenicity (ASCO)Febrile NeutropeniaGastrointestinal ToxicityHepatotoxicityInfectionsLeukopeniaNeutropeniaThrombocytopenia below 50 000/µl only studiesPublicationAuthorBuckner JCvan den Bent MJ DiseaseGliome WHO-Grad 2, Erstlinie, ECOG 0-2Neu diagnostiziertes, nicht 1p/19q kodeletiertes anaplastisches Gliom WHO Grad 2 oder 3, ECOG 0-2OriginBrain Tumour Centre at Erasmus, Rotterdam, Netherlands, CATNON trial (EORTC study 26053-22054)Mayo Clinic, Rochester, USAProtocols in Revision 4 protocols foundProtocols under revision.Lomustine 110 / Vincristine 2 / Procarbazine 60 / Radiation, Glioma (PID1694 V1.2)Temozolomide 150, Glioma, cycle 2 (PID1453 V1.2)Temozolomide 200, Glioma, Cycle 3-13 (PID1454 V1.2)Temozolomide 75 / Radiation, Glioma, Cycle 1 (PID1452 V1.2)
